[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500046":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":32,"centralContacts":37,"locations":43,"responsibleParty":57,"collaborators":27,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":27,"enrollmentInfo":69,"targetDuration":27,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":46,"whyStopped":27,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Besancon","OTHER",[8,14,18],{"label":9,"type":6,"description":10,"interventionNames":11},"IgA nephropathy in follow-up (arm 1)","Diagnosis of IgA nephropathy from 2009, with a minimum follow-up for nephropathy of 5 years",[12,13],"Other: Blood collection","Other: Urine sample",{"label":15,"type":6,"description":16,"interventionNames":17},"Newly diagnosed IgA nephropathy (arm 2)","Diagnosis of IgA nephropathy during the study period",[12,13],{"label":19,"type":6,"description":20,"interventionNames":21},"CD163s control (arm 3)","Diagnosis of Lupus or ANCA-associated vasculitis or polycystic kidney disease",[13],[23,28],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Blood collection","Collection of 3 blood tubes at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2)",[9,15],null,{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Urine sample","Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)",[19,9,15],[33],{"name":34,"affiliation":35,"role":36},"Melchior Chabannes, MD","Nephrology, CHU Besançon","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":27,"email":42},"Charline Vauchy, PhD.","CONTACT","0381218875","cvauchy@chu-besancon.fr",[44],{"facility":45,"status":46,"city":47,"state":27,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":27},"Centre Hospitalier Universitaire de Besançon","RECRUITING","Besançon","25000","France","FR",{"type":52,"coordinates":53},"Point",[54,55],6.01815,47.24878,{"lat":55,"lon":54},{"type":58,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100500046","interest-of-follicular-helper-lymphocytes--regulatory-follicular-helper-lymphocytes-ratio-in-iga-nephropathy-100500046",false,"NCT05791162","Interest of Follicular Helper Lymphocytes \u002F Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy","Interest of Follicular Helper Lymphocytes \u002F Regulatory Follicular Helper Lymphocytes Ratio to Characterize and Predict Poor Prognosis Forms in IgA Nephropathy: an Exploratory Proof-of-concept Study","LYMFONI","Inclusion Criteria:\n\n* IgA nephropathy histologically proven on renal biopsy according to KDIGO criteria, with 8 permeable glomeruli (patients diagnosed from 2009 with a minimum follow-up for their nephropathy of 5 years (arm 1) or patients diagnosed during the study (arm 2))\n\nControl patients: Lupus or ANCA-associated vasculitis or polycystic kidney disease (arm 3)\n\nExclusion Criteria:\n\n* Legal incapacity or limited legal capacity\n* Subjects with no social security coverage.\n* Pregnancy \u002F No effective contraceptive method","ALL","18 Years",{"count":70,"type":71},75,"ESTIMATED","INTERVENTIONAL",[74],"NA","This study aims to investigate the relevance of the Tfh\u002FTfr (Follicular helper T cells\u002F Follicular regulatory T cells) ratio in patients with IgA nephropathy:\n\n* To identify a differential expression of the Tfh\u002FTfr ratio in patients considered stable or progressive\n* To predict, at diagnosis, the clinical evolution of the disease (progressive or stable form) in the first year.",[77],"Glomerulonephritis, IGA",[79,80],"Follicular helper T cells","Follicular regulatory T cells","2024-11-19",{"date":83,"type":84},"2024-11-21","ACTUAL",{"date":86,"type":84},"2023-05-23",{"date":88,"type":71},"2026-05",{"name":5,"class":6},1]